A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders
Citations
4,274 citations
Cites background or result from "A Gain-of-Function Mutation of JAK2..."
...It is recommended, however, that the cytogenetic abnormality be included in the diagnostic report, for example, “therapy-related AML with t(9;11)(p22;q23)....
[...]
...Three new cytogenetically defined entities are added: (1) AML with t(6;9)(p23;q34); DEK-NUP214, (2) AML with inv(3)(q21q26....
[...]
...1;q22), and APL with t(15; 17)(q22;q12) are considered as acute leukemia regardless of blast count in the PB or BM, but in contrast to the previous edition, for AML with t(9;11)(p22;q23) or other 11q23 abnormalities, as well as for all other subgroups (except the rare instance of some cases of erythroleukemia) blasts of 20% or more of white blood cells in PB or of all nucleated BM cells is required for the diagnosis of AML....
[...]
...Mixed phenotype acute leukemia with t(9;22)(q34;q11....
[...]
...B lymphoblastic leukemia/lymphoma with t(9;22)(q34;q11....
[...]
2,497 citations
Cites background from "A Gain-of-Function Mutation of JAK2..."
...Busque L, Patel JP, Figueroa ME, et al. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis....
[...]
...Detectable clonal expansions most frequently involved somatic mutations in three genes (DNMT3A, ASXL1, and TET2) that have previously been implicated in hematologic cancers....
[...]
...Three of these four genes — DNMT3A, TET2, and ASXL1 — also tend to harbor such mutations in hematologic cancers19-21 and are proposed to function as epigenetic regulators.22 Mutations in PPM1D, which functions as a regulator of tumor-suppressor protein p53,23 have been described more frequently in nonhematologic cancers....
[...]
...Reflecting this relationship, participants having clonal hematopoiesis with candidate drivers were, on average, older than those without detectable putative somatic mutations (mean age, 64 years vs. 55 years; P<0.001); each of the most common driver genes (DNMT3A, ASXL1, TET2, PPMD1, and JAK2) also tended to have detectable somatic mutations in older persons (Fig....
[...]
...Most cases of clonal hematopoiesis appeared to involve mutations in a specific subset of the genes recognized as drivers of blood cancers,22 such as DNMT3A, ASXL1, and TET2 (Fig....
[...]
2,492 citations
1,658 citations
1,649 citations
References
2,155 citations
1,305 citations
1,110 citations
830 citations